共 44 条
[1]
Kimball AB(2005)The psychosocial burden of psoriasis Am J Clin Dermatol 6 383-92
[2]
Jacobson C(2007)Pathogenesis and clinical features of psoriasis Lancet 370 263-71
[3]
Weiss S(2020)The association of metabolic syndrome and psoriasis: a systematic review and meta-analysis of observational study Endocr Metab Immune Disord Drug Targets 20 703-17
[4]
Vreeland MG(2017)The role of IL-17 in the treatment of psoriatic arthritis Expert Rev Clin Immunol 13 815-21
[5]
Wu Y(2015)Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis Expert Opin Biol Ther 15 1727-37
[6]
Griffiths CE(2018)The IL-17 family of cytokines in psoriasis: IL-17A and beyond Front Immunol 9 1682-93
[7]
Barker JN(2015)Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE) Br J Dermatol 172 484-9
[8]
Choudhary S(2017)Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study JAm Acad Dermatol 76 60-38
[9]
Pradhan D(2014)Secukinumab in plaque psoriasis-results of two phase 3 trials N Engl J Med 371 326-90
[10]
Pandey A(2015)Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE) J Eur Acad Dermatol Venereol 29 1082-14